Standalone June quarter revenue up 28.6%, profit after tax down 30.9%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the standalone quarter ended 30 June 2026, revenue from operations was INR 2,379.06 lakh, up 28.6% from INR 1,850.04 lakh a year earlier. Other operating income was INR 346.03 lakh versus nil; product sales rose 9.9%. Profit after tax fell 30.9% to INR 39.42 lakh from INR 57.02 lakh. The margin before interest, tax, depreciation and amortisation, excluding other operating income, fell from 4.0% to negative 11.0%.
Growth relied on other operating income, while core operating profit turned negative and profit after tax fell. The result may weigh on the stock.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.